Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06167681 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 1, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Eligibility criteria shortened, about 133 words Secondary endpoints: 5 to 2v5 Show 1 more changeShow less
    • Secondary endpoints: 5 to 2

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2023 to Jan 17, 2024 · Site details revised at 2 of 2 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2023 to Jan 17, 2024
    • Site details revised at 2 of 2 sites
  4. Eligibility criteria shortened, about 24 words Secondary endpoints revised (5) · Study description shortened, about 10 wordsv2 Show 2 more changesShow less
    • Secondary endpoints revised (5)
    • Study description shortened, about 10 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
Trial Details
NCT Number NCT06167681
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Parkinson Disease
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov